Bohai Pharmaceuticals Group (OTCBB/OTCQB: BOPH)

Legal Notices and Disclosures

Cautionary Note Regarding Forward-Looking Statements

The content of this website (including material which is linked to this website) contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in Bohai's filings with the Securities and Exchange Commission.

Forward-looking statements may include, without limitation, statements regarding Bohai's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of Bohai's management; however, actual results, including, without limitation, actual sales and other financial results, may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve risks and uncertainties that are subject to change based on various factors (many of which are beyond the Bohai's control).

Estimates and projections provided on this site and otherwise by Bohai have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates and projections will be achieved, if at all.

Bohai disclaims any intent or obligation to update its forward-looking statements.

SEC Section 17(b) Disclosure

Trilogy Capital Partners, Inc. (“Trilogy”) has been engaged by Bohai Pharmaceuticals Group, Inc. ("BOPH") to provide investor relations services for compensation of a monthly retainer in the amount of $12,500. Trilogy Capital Partners owns 31,250 shares of the Common Stock of BOPH. In addition, Alfonso J. Cervantes, the principal of Trilogy, beneficially owns 90,000 shares of the Common stock of BOPH through La Mancha Capital Group, LLC, a limited liability company and is a non-managing member of Regeneration Capital Group, LLC, which owns 541,875 shares of the Common Stock of BOPH.